<DOC>
	<DOCNO>NCT01216826</DOCNO>
	<brief_summary>The purpose study determine Everolimus aim response child adolescents refractory relapse osteosarcoma . The aim response define complete partial response ( accord RECIST criterion ) least 4 week , stable disease least 12 week .</brief_summary>
	<brief_title>Phase II Study Everolimus Children Adolescents With Refractory Relapsed Osteosarcoma</brief_title>
	<detailed_description />
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Osteosarcoma histological confirmation . No option know curative treatment , neither approve treatment increase survival adequate quality life . Karnofsky scale ≥ 50 patient 16 year Lansky scale ≥ 50 patient 16 year . Subjects receive antineoplastic therapy &lt; 4 week study treatment initiation . Adequate hematological function : neutrophil count &gt; 1.500/mm³ , platelet &gt; 100.000/mm³ hemoglobin &gt; 8.0 mg/dL . Adequate renal function , define : Age Maximum serum creatinine ( mg/dL ) 0 29 day 0,4 0,7 1 month 3 year 0,7 4 7 year 0,8 8 10 year 0,9 11 12 year 1,0 13 17 year 1,2 ≥18 year 1,3 Adequate hepatic function : total bilirubin ≤ 1.5 x ULN transaminases ≤ 2.5 x ULN . Patient and/or legal responsible must sign ICF . Life expectation &gt; 8 week . Measurable disease , accord RECIST criterion . For female patient childbearing age : Presence negative pregnancy test within 7 day prior day 0 . The patient agree use effective contraception procreative potential exists . Use reliable mean contraception ( e.g . hormonal contraceptive , patch , vaginal ring , intrauterine device , physical barrier , abstinence ) subject reproductive potential ( male female ) require study treatment 3 month follow last dose study drug History myocardial infarction , angina cerebrovascular accident relate atherosclerosis . Pulmonary disorder ( e.g . FEV1 DLCO ≤ 70 % upper expect ) . Significant hematologic hepatic abnormality ( transaminase level &gt; 2.5 x ULN serum bilirubin &gt; 1.5 x ULN , hemoglobin &lt; 8 g/dL , platelet &lt; 100.000/ mm3 , ANC &lt; 1.500/mm3 ) . Has exist serious medical condition could adversely affect ability patient treat accordance protocol . Any condition , therapy , medical condition , , opinion attend physician could represent risk patient adversely affect study objective . If female , pregnant lactating . Active infection moment recruitment . Previous history organ transplantation . Recent surgery &lt; 2 month enter study . Concomitant antineoplastic therapy . Patient receive one rescue treatment , previously . Previous treatment mTor inhibitor ( ex : sirolimus , temsirolimus , everolimus ) . Use investigational drug &lt; 30 day enter study . Noncontrolled hyperlipidaemia : serum cholesterol ( fast ) &gt; 300 mg/dL 7,75 mmol/L triglyceride ( fast ) &gt; 2,5 x ULN . Noncontrolled diabetes mellitus define : glycemia ( fast ) &gt; 1.5 x ULN . Patient hemorrhagic disorder use oral antivitamin K ( except warfarin low dos ) . Patient HIV infection . Incapable perform protocol visit . Another neoplasia last 2 year ( except squamous basocellular skin cancer ) . Hypersensitivity history rapamycin analog . Chronic treatment corticoid ( except per oral , topical local treatment ) another immunosuppressor agent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>